Literature DB >> 11356949

Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations.

R Seifert1, K Wenzel-Seifert, U Gether, B K Kobilka.   

Abstract

The interaction of an agonist-bound G-protein-coupled receptor (GPCR) with its cognate G-protein initiates a sequence of experimentally quantifiable changes in both the GPCR and G-protein. These include the release of GDP from G(alpha), the formation of a ternary complex between the nucleotide-free G-protein and the GPCR, which has a high affinity for agonist, followed by the binding of GTP to G(alpha), the dissociation of the GPCR/G-protein complex, and the hydrolysis of GTP. The efficacy of an agonist is a measure of its ability to activate this cascade. It has been proposed that efficacy reflects the ability of the agonist to stabilize the active state of the GPCR. We examined a series of beta(2)-adrenoceptor (beta(2)AR) agonists (weak partial agonists to full agonists) for their efficacy at promoting two different steps of the G-protein activation/deactivation cycle: stabilizing the ternary complex (high-affinity, GTP-sensitive agonist binding), and steady-state GTPase activity. We obtained results for the wild-type beta(2)AR and a constitutively active mutant of the beta(2)AR (beta(2)AR(CAM)) using fusion proteins between the GPCRs and G(salpha) to facilitate GPCR/G-protein interactions. There was no correlation between efficacy of ligands in activating GTPase and their ability to stabilize the ternary complex at beta(2)AR(CAM). Our results suggest that the GPCR state that optimally promotes the GDP release and GTP binding is different from the GPCR state that stabilizes the ternary complex. By strongly stabilizing the ternary complex, certain partial agonists may reduce the rate of G-protein turnover relative to a full agonist.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356949

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

Review 1.  G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin.

Authors:  J Ballesteros; K Palczewski
Journal:  Curr Opin Drug Discov Devel       Date:  2001-09

Review 2.  Opioid receptor regulation.

Authors:  Mark von Zastrow
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

3.  Time-resolved fluorescence ligand binding for G protein-coupled receptors.

Authors:  Alexander Emami-Nemini; Thomas Roux; Marion Leblay; Emmanuel Bourrier; Laurent Lamarque; Eric Trinquet; Martin J Lohse
Journal:  Nat Protoc       Date:  2013-06-13       Impact factor: 13.491

Review 4.  Single-cell analysis of G-protein signal transduction.

Authors:  Terri Clister; Sohum Mehta; Jin Zhang
Journal:  J Biol Chem       Date:  2015-01-20       Impact factor: 5.157

Review 5.  Advances in receptor conformation research: the quest for functionally selective conformations focusing on the β2-adrenoceptor.

Authors:  Anthony Yiu-Ho Woo; Ying Song; Weizhong Zhu; Rui-Ping Xiao
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

6.  Interaction of fenoterol stereoisomers with β2-adrenoceptor-G sα fusion proteins: antagonist and agonist competition binding.

Authors:  Michael T Reinartz; Solveig Kälble; Irving W Wainer; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-01-31       Impact factor: 3.000

7.  Regulation of G protein subunit composition in cardiomyocytes: pharmacological implications.

Authors:  Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-09       Impact factor: 3.000

8.  Regulation of the avidity of ternary complexes containing the human 5-HT(1A) receptor by mutation of a receptor contact site on the interacting G protein alpha subunit.

Authors:  Philip J Welsby; I Craig Carr; Graeme Wilkinson; Graeme Milligan
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

9.  Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor.

Authors:  Francesca Magnani; Yoko Shibata; Maria J Serrano-Vega; Christopher G Tate
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-29       Impact factor: 11.205

10.  Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors.

Authors:  Jan Jakubík; Alena Randáková; Esam E El-Fakahany; Vladimír Dolezal
Journal:  BMC Pharmacol       Date:  2009-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.